one delay doesnt make the case.
historically fda meets 90-95 % of their deadline. I'll be waiting for to see the annual fda performance data before jumping to conclusion.
if you dig down there could be other reasons for a delay other than staff cuts.
Apparently drug reviewers havent been cut . Their supporting staff have been. Ai might be able to fill that gap. But it's only just been introduced.
in this case a specific division has an unusually high workload.
another delay occurded because fda changed course late cycle and suddenly wanted to have an advisory committe
https://www.fiercebiotech.com/biotech/fda-delays-decision-biohaven-filing-and-plans-adcomm-sinking-stock
- Forums
- ASX - By Stock
- Cell Therapy News/Articles
MSB
mesoblast limited
Add to My Watchlist
1.64%
!
$1.80

one delay doesnt make the case. historically fda meets 90-95 %...
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$1.80 |
Change
-0.030(1.64%) |
Mkt cap ! $2.293B |
Open | High | Low | Value | Volume |
$1.80 | $1.83 | $1.76 | $10.01M | 5.615M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
18 | 18585 | $1.80 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.80 | 14905 | 15 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
17 | 34706 | 1.785 |
19 | 180203 | 1.780 |
8 | 20951 | 1.775 |
9 | 57396 | 1.770 |
10 | 61246 | 1.765 |
Price($) | Vol. | No. |
---|---|---|
1.790 | 68472 | 31 |
1.795 | 35400 | 14 |
1.800 | 64937 | 9 |
1.805 | 105939 | 8 |
1.810 | 75212 | 6 |
Last trade - 15.15pm 18/06/2025 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |
The Watchlist
MEM
MEMPHASYS LIMITED.
Professor John Aitken, Scientific Director
Professor John Aitken
Scientific Director
Previous Video
Next Video
SPONSORED BY The Market Online